SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that interim data from a first-in-man phase I clinical trial demonstrated that a DNA-based immunotherapy (plasmid IL-12) against metastatic melanoma, delivered using Inovio’s electroporation delivery technology, was safe and also produced durable local and systemic tumor regression. Inovio’s electroporation delivery technology is intended to enhance the potency of DNA-based immunotherapies, including DNA vaccines, against cancers and infectious diseases.
